Oncologic Outcomes in Patients with Localized, Primary Head and Neck Synovial Sarcoma
Cancers · 09.12.2024 · 16 (23) · 4119
DOI: 10.3390/cancers16234119 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 09.12.2024. Verfasst von Riddhi R Patel und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, |1515 Holcombe Blvd., Houston, TX 77030, USA. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background: this study aims to evaluate the survival outcomes of patients suffering from head and neck synovial sarcoma (HNSS), especially in relation to patients with a localized disease at diagnosis. Methods: this retrospective chart review includes 57 patients diagnosed with primary HNSS between 1981 and 2020 who presented with a localized disease at diagnosis. Overall survival (OS) from diagnosis, local recurrence-free survival (LRFS), and metastasis-free survival (MFS) from the end of the primary tumor treatment are estimated. The Kaplan–Meier method, the log-rank test, and the Cox proportional hazards regression are used. Results: the 5-year OS, LRFS, and MFS are estimated at 80.4% (95% CI: 66.6%, 88.9%), 67.7% (95% CI: 50.0%, 80.4%), and 50.6% (95% CI: 34.4%, 64.8), respectively. Compared to patients undergoing surgical resection alone, those receiving radiation therapy (RT) with surgery have better LRFS (HR: 0.03, 95% CI: 0.001, 0.57), and those undergoing neo/adjuvant chemotherapy with surgery and RT have better MFS (HR: 0.10, 95% CI: 0.01, 0.95). Moreover, among the patients with tumors ≥ 4 cm, those subject to neo/adjuvant chemotherapy have significantly better MFS (5-year MFS: 53.2%, 95% CI: 29.0%, 72.5%) than those treated with surgery and RT alone (5-year MFS: 20.0%, 95% CI: 0.8%, 58.2%) (LR-p = 0.003). Conclusions: overall, the prognosis of HNSS patients looks favorable. Perioperative RT significantly improves local control, and perioperative chemotherapy plays a vital role in delaying metastasis formation in patients with primary HNSS when diagnosed with a localized disease. Importantly, we recommend that systemic therapy should be considered for HNSS patients with tumors ≥ 4 cm.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, |1515 Holcombe Blvd., Houston, TX 77030, USA.
- Division of Epidemiology, The University of Texas School of Public Health, 1200 Pressler St., Houston, TX 77030, USA.
- Division of Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA.
- Division of Diagnostic Radiology-Musculoskeletal Imaging, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA.
- Department of Pathology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA.
- Department of Orthopedic Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA.
ORCID-Profile: Riddhi R Patel, Vancheswaran Gopalakrishnan, Patrick P Lin, Dejka M Araujo
Zitieren
APA
Patel, R. R., Gopalakrishnan, V., Amini, B., Lazar, A. J., Lin, P. P., Benjamin, R. S., Bishop, A. J., Goepfert, R. P., & Araujo, D. M. (2024). Oncologic Outcomes in Patients with Localized, Primary Head and Neck Synovial Sarcoma. Cancers, 16(23), 4119. https://doi.org/10.3390/cancers16234119
Vancouver
Patel RR, Gopalakrishnan V, Amini B, Lazar AJ, Lin PP, Benjamin RS, et al. Oncologic Outcomes in Patients with Localized, Primary Head and Neck Synovial Sarcoma. Cancers. 2024;16(23):4119. doi:10.3390/cancers16234119
BibTeX
@article{Patel2024,
author = {Patel, Riddhi R and Gopalakrishnan, Vancheswaran and Amini, Behrang and Lazar, Alexander J and Lin, Patrick P and Benjamin, Robert S and Bishop, Andrew J and Goepfert, Ryan P and Araujo, Dejka M},
title = {Oncologic Outcomes in Patients with Localized, Primary Head and Neck Synovial Sarcoma},
journal = {Cancers},
year = {2024},
volume = {16},
number = {23},
pages = {4119},
doi = {10.3390/cancers16234119}
}
EUVIMED